Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer

被引:62
作者
Montano, X [1 ]
Djamgoz, MBA [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Neurosci Solut Canc Res Grp, Mol Signalling Grp, Dept Biol Sci, London SW7 2AZ, England
关键词
prostate cancer; metastatis; neurotrophins; trk; epidermal growth factor receptor; epidermal growth factor;
D O I
10.1016/j.febslet.2004.06.088
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Although cancer of the prostate (CaP) is the most commonly occurring cancer in males, there are major limitations in its diagnosis and long-term cure. Consequently, understanding the molecular mechanisms involved in the progression of CaP is of particular importance for production of pharmacological and biological agents to manage the disease. The development of the normal prostate is regulated by stromal-epithelial interactions via endocrine and paracrine factors, such as androgens and growth factors, which act as precise homeostatic regulators of cellular proliferation. Importantly, after a period of hormonal therapy, CaP shifts from an androgen-dependent to an androgen-independent state with a concomitant switch from paracrine to autocrine growth factor stimulation and subsequent upregulation of growth factor expression. Thus, growth factors and their receptors have a pivotal role in CaP. This is emphasized by current evidence obtained from clinical specimens as well as several in vitro and in vivo models strongly suggesting that epidermal growth factor and the neurotrophins (nerve growth factor, brain derived neurotrophin factor, neurotrophin-3 and neurotrophin-4/5) together with their tyrosine kinase receptors could play a very significant role in CaP progression. (C) 2004 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 87 条
[1]   Molecular genetics of prostate cancer [J].
Abate-Shen, C ;
Shen, MM .
GENES & DEVELOPMENT, 2000, 14 (19) :2410-2434
[2]   Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault [J].
Arnold, JT ;
Isaacs, JT .
ENDOCRINE-RELATED CANCER, 2002, 9 (01) :61-73
[3]  
Aumüller G, 2001, PROSTATE, V46, P108, DOI 10.1002/1097-0045(20010201)46:2<108::AID-PROS1014>3.0.CO
[4]  
2-9
[5]   Growth factors and their receptors: New targets for prostate cancer therapy [J].
Barton, J ;
Blackledge, G ;
Wakeling, A .
UROLOGY, 2001, 58 (2A) :114-122
[6]   Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin [J].
Baselga, J ;
Pfister, D ;
Cooper, MR ;
Cohen, R ;
Burtness, B ;
Bos, M ;
D'Andrea, G ;
Seidman, A ;
Norton, L ;
Gunnett, K ;
Falcey, J ;
Anderson, V ;
Waksal, H ;
Mendelsohn, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :904-914
[7]   Monoclonal antibodies directed at growth factor receptors [J].
Baselga, J .
ANNALS OF ONCOLOGY, 2000, 11 :187-190
[8]   Neurotrophin-evoked depolarization requires the sodium channel NaV1.9 [J].
Blum, R ;
Kafitz, KW ;
Konnerth, A .
NATURE, 2002, 419 (6908) :687-693
[9]   Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status [J].
Bonkhoff, H .
ANNALS OF ONCOLOGY, 2001, 12 :S141-S144
[10]  
Bonkhoff H, 1996, PROSTATE, V28, P98